Sudeep Pharma
Market cap ₹13,579 Cr
- P/E
- 71.35
- Day range
- ₹1,175.30 – ₹1,227.80
- 52-week range
- ₹524.05 – ₹1,378.00
- Volume
- 1.03 L
- Open
- ₹1,210.30
- Prev close
- ₹1,217.50
Latest results · Q2 FY27(consolidated)Revenue ₹197 Cr+20.9%Profit ₹52 Cr+10.8%Margin 26.3%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
SUDEEPPHRM in NSE indices and F&O
Research profile
Composite 57 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.4%
- Graham no.
- ₹177.14
- vs Graham
- -85.3%
- ROE ÷ P/B
- 1.8%
- Magic Formula
- #340
- Piotroski
- 3/6
- FCF yield
- -0.4%
- PEG
- 6.72
Appears in 11 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 44 in Chemicals| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Solar IndustriesSOLARINDS | ₹1.68 L Cr | 74.04 | 22.19 | 32.5% | 38.0% | 29.0% | 0.23 | +69.0% |
| Pidilite IndustriesPIDILITIND | ₹1.56 L Cr | 58.12 | 14.05 | 24.0% | 31.0% | 20.0% | 0.03 | +20.9% |
| SRF LtdSRF | ₹72,471 Cr | 31.75 | 4.80 | 13.8% | 15.0% | 19.0% | 0.35 | +34.7% |
| Linde IndiaLINDEINDIA | ₹58,548 Cr | 118.46 | 13.42 | 13.6% | 18.0% | 32.0% | 0.23 | +12.3% |
| Coromandel InternationalCOROMANDEL | ₹57,701 Cr | 37.01 | 4.30 | 16.1% | 22.0% | 9.0% | 0.12 | +6.6% |
| Gujarat FluorochemicalsFLUOROCHEM | ₹52,952 Cr | 78.39 | 6.17 | 7.6% | 10.0% | 27.0% | 0.28 | +45.5% |
| Navin Fluorine InternationalNAVINFLUOR | ₹52,759 Cr | 57.95 | 11.37 | 20.1% | 21.0% | 34.0% | 0.28 | +57.1% |
| Sudeep PharmaSUDEEPPHRM | ₹13,579 Cr | 71.35 | 14.36 | 25.3% | 28.0% | 37.0% | 0.20 | +20.9% |
| Sector median | ₹13,505 Cr | 31.75 | 2.86 | 9.9% | 12.0% | 15.7% | 0.27 | +21.5% |
Sector as classified in the tracked universe; medians use every tracked Chemicals company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 3h agoHeadlines about Sudeep Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 73.1
- Price / Book
- 14.18
- ROE (FY26)
- 25.3%
- ROCE (latest year)
- 28%
- Dividend yield
- 0.12%
Moving averages (NSE)
- 20-day
- ₹1,116.33
- Price above
- 50-day
- ₹1,137.62
- Price above
- 200-day
- ₹858.82
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 | 197 |
| Expenses | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 | 123 |
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 | 73 |
| OPM % | 43% | 34% | 37% | 35% | 34% | 35% | 34% | 35% | 37% |
| Other Income | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 | 6 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 3 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 |
| Profit before tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 | 71 |
| Tax % | 21% | 24% | 24% | 29% | 21% | 23% | 23% | 25% | 27% |
| Net Profit | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 | 52 |
| EPS in Rs | ₹4.38 | ₹2.58 | ₹3.97 | ₹2.77 | ₹4.11 | ₹4.20 | ₹4.33 | ₹3.59 | ₹4.56 |
From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+35 days since Mar 2021
+277 days since Mar 2021
+34 days since Mar 2021
+279 days since Mar 2021
+162 days since Mar 2021
Strengths, risks & growth
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries. [1]
Strengths
- Company has delivered good profit growth of 39.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%
Risks
- Stock is trading at 14.4 times its book value
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +24%
- 3 Years
- +14%
- TTM
- +27%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +39%
- 3 Years
- +40%
- TTM
- +26%
Return on Equity
- 10 Years
- —
- 5 Years
- +32%
- 3 Years
- +32%
- Last Year
- +25%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 76.16% | 76.16% | 76.16% | 76.16% | 0.00 pp |
| FII | 1.67% | 1.55% | 1.81% | 2.93% | +1.12 pp |
| DII | 17.59% | 18.11% | 15.64% | 14.06% | -1.58 pp |
| Public | 4.57% | 4.18% | 6.39% | 6.87% | +0.48 pp |
Filed with NSE for Sept 2026: promoters 76.15%, public 23.85%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 7.43% (+1.96 pp)- Promoters76.2%
- Foreign institutions2.9%
- Mutual funds7.4%
- Insurance1.0%
- Other domestic institutions5.6%
- Retail4.1%
- Others2.8%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Axis Small Cap Fund | 1.55% | 0.73% | +0.14 pp |
| SBI Healthcare Opp Fund | 1.02% | 2.39% | +0.18 pp |
| HDFC Manufacturing Fund | 0.68% | 0.91% | +0.22 pp |
| SBI MNC Fund | 0.53% | 1.20% | +0.26 pp |
| SBI Comma Fund | 0.53% | 6.35% | +1.24 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Avg
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 239 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 48.1%
- Downside volatility
- 43.1%
- Worst 5% of days
- 5.1%
- Average of that tail
- 5.7%
- Max drawdown (1Y)
- 31.5%
- Below its peak
- 10.6%
Against the market
- Beta vs Nifty 50
- 0.79
- Correlation
- 0.24
- Relative strength (3M)
- +5.3%
- ATR (14)
- 4.9%
Return
- Return 1M
- +20.1%
- Return 3M
- +9.1%
- Return 6M
- +85.2%
- Return 1Y
- —
- vs 200-day average
- +40.0%
Momentum
- RSI (14)
- 59.3
- MACD histogram
- 11.41
- Stochastic %K
- 73.2
- ADX (14)
- 27.0
- +DI / −DI
- 22.7 / 15.6
- Money flow index
- 74.9
Participation
- Delivery (20d avg)
- 45.5%
- vs its 60-day baseline
- -3.9 pts
- Volume vs 20-day
- -0.7σ
- Close vs day's VWAP
- +0.3%
- 52-week position
- 83 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
3 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- -₹49 Cr
- FCF yield
- -0.4%
- Net debt
- ₹136 Cr
- Net debt / equity
- 0.14
- EV / sales
- 19.57
- PEG
- 6.72
- Revenue CAGR
- 20.9%
- Profit CAGR
- 10.8%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹1.50
Dividend - Rs 1.50 Per Share
23 Jul 2026ex-date
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- Aug 2026Slides
- Aug 2026Slides
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlides
Credit ratings
- Rating update · 1 Mar 2016 from icra
- Rating update · 19 Jan 2016 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 29 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Sudeep Pharma: common questions
Answered from the figures on this page.